Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting effector pathways in RAC1P29S-driven malignant melanoma.

Small GTPases - 1 Jul 2021

Uribe-Alvarez Cristina, Guerrero-Rodríguez Sandra Lucía, Rhodes Jennifer, Cannon Alexa, Chernoff Jonathan, Araiza-Olivera Daniela

Abstract excerpt

Malignant melanoma is characterized by mutations in a number of driver genes, most notably BRAF and NRAS. Recent genomic analyses revealed that 4-9% of sun-exposed melanomas bear activating mutations in RAC1, which encodes a small GTPase that is known to play key roles in cell proliferation, survival, and migration. The RAC1 protein activates several effector pathways, including Group A p21-activated kinases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Trans-Activators
Share to Apoptosis
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Melanoma

Share to Mutation

Share to Signal Transduction

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 32043900
DOI: 10.1080/21541248.2020.1728469
PMCID: PMC8205048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting effector pathways in RAC1P29S-driven malignant melanoma.PMID 32043900Read ↗

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibitionSemantic proximity Read ↗

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy ResistanceSemantic proximity Read ↗

Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.Semantic proximity Read ↗

RACK1 cooperates with NRASQ61K to promote melanoma in vivo.Semantic proximity Read ↗

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanomaSemantic proximity Read ↗

Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven CancersSemantic proximity Read ↗

RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.Semantic proximity Read ↗

Ras-Associated Protein-1 Regulates Extracellular Signal-Regulated Kinase Activation and Migration in Melanoma Cells: Two Processes Important to Melanoma Tumorigenesis and MetastasisSemantic proximity Read ↗

RAC1 and melanoma.Semantic proximity Read ↗

Nras in melanoma: targeting the undruggable target.Semantic proximity Read ↗

Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation.Semantic proximity Read ↗

Characterisation and outcome of RAC1 mutated melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.